Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of BioMedical Research (DBMR), University of Bern, Bern, Switzerland.
Br J Cancer. 2024 Nov;131(8):1350-1362. doi: 10.1038/s41416-024-02831-3. Epub 2024 Aug 30.
Non-small cell lung cancer (NSCLC) is characterised by its aggressiveness and poor prognosis. Early detection and accurate prediction of therapeutic responses remain critical for improving patient outcomes. In the present study, we investigated the potential of circulating microRNA (miRNA) as non-invasive biomarkers in patients with NSCLC.
We quantified miRNA expression in plasma from 122 participants (78 NSCLC; 44 healthy controls). Bioinformatic tools were employed to identify miRNA panels for accurate NSCLC diagnosis. Validation was performed using an independent publicly available dataset of more than 4000 NSCLC patients. Next, we correlated miRNA expression with clinicopathological information to identify independent prognostic miRNAs and those predictive of anti-PD-1 treatment response.
We identified miRNA panels for lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) diagnosis. The LUAD panel consists of seven circulating miRNAs (miR-9-3p, miR-96-5p, miR-147b-3p, miR-196a-5p, miR-708-3p, miR-708-5p, miR-4652-5p), while the LUSC panel comprises nine miRNAs (miR-130b-3p, miR-269-3p, miR-301a-5p, miR-301b-5p, miR-744-3p, miR-760, miR-767-5p, miR-4652-5p, miR-6499-3p). Additionally, miR-135b-5p, miR-196a-5p, miR-31-5p (LUAD), and miR-205 (LUSC) serve as independent prognostic markers for survival. Furthermore, two miRNA clusters, namely miR-183/96/182 and miR-767/105, exhibit predictive potential in anti-PD-1-treated LUAD patients.
Circulating miRNA signatures demonstrate diagnostic and prognostic value for NSCLC and may guide treatment decisions in clinical practice.
非小细胞肺癌（NSCLC）具有侵袭性和预后不良的特点。早期发现和准确预测治疗反应仍然是改善患者预后的关键。本研究旨在探讨循环 microRNA（miRNA）作为 NSCLC 非侵入性生物标志物的潜力。
我们定量分析了 122 名参与者（78 名 NSCLC；44 名健康对照者）血浆中的 miRNA 表达。利用生物信息学工具鉴定用于准确诊断 NSCLC 的 miRNA 谱。使用超过 4000 名 NSCLC 患者的独立公开数据集进行验证。然后，我们将 miRNA 表达与临床病理信息相关联，以鉴定独立的预后 miRNA 和预测抗 PD-1 治疗反应的 miRNA。
我们鉴定了用于肺腺癌（LUAD）和鳞状细胞癌（LUSC）诊断的 miRNA 谱。LUAD 谱由七个循环 miRNA（miR-9-3p、miR-96-5p、miR-147b-3p、miR-196a-5p、miR-708-3p、miR-708-5p、miR-4652-5p）组成，而 LUSC 谱由九个 miRNA（miR-130b-3p、miR-269-3p、miR-301a-5p、miR-301b-5p、miR-744-3p、miR-760、miR-767-5p、miR-4652-5p、miR-6499-3p）组成。此外，miR-135b-5p、miR-196a-5p、miR-31-5p（LUAD）和 miR-205（LUSC）是生存的独立预后标志物。此外，miR-183/96/182 和 miR-767/105 两个 miRNA 簇在抗 PD-1 治疗的 LUAD 患者中具有预测潜力。
循环 miRNA 特征对 NSCLC 具有诊断和预后价值，并可能指导临床实践中的治疗决策。
